Cefamandole Nafate Free Base
The free base form of cefamandole nafate is a parenteral second-generation cephalosporin prodrug converted to active cefamandole in the body. It is used for treating susceptible gram-positive and gram-negative bacterial infections. Caution is warranted regarding its interaction with alcohol and potential effects on vitamin K-dependent clotting factors.
분자량
490.5000 g/mol
LogP
-0.30
TPSA
207.00 Ų
리핀스키 5의 법칙
통과
작용 기전
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
2D 구조
Cite this structure
Embed this structure
SMILES
Cn1nnnc1SCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](OC=O)c3ccccc3)[C@H]2SC1
InChI
InChI=1S/C19H18N6O6S2/c1-24-19(21-22-23-24)33-8-11-7-32-17-12(16(28)25(17)13(11)18(29)30)20-15(27)14(31-9-26)10-5-3-2-4-6-10/h2-6,9,12,14,17H,7-8H2,1H3,(H,20,27)(H,29,30)/t12-,14-,17-/m1/s1
Molecular Formula
C19H18N6O6S2
HBD / HBA
2 / 11
회전 가능 결합
9
무거운 원자
33
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
자주 묻는 질문
The free base form of cefamandole nafate is a parenteral second-generation cephalosporin prodrug converted to active cefamandole in the body. It is used for treating susceptible gram-positive and gram-negative bacterial infections. Caution is warranted regarding its interaction with alcohol and potential effects on vitamin K-dependent clotting factors.
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Yes, Cefamandole Nafate Free Base is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201218. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5284527. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="cefamandole-nafate-free-base"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/cefamandole-nafate-free-base/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/cefamandole-nafate-free-base/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/cefamandole-nafate-free-base/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="cefamandole-nafate-free-base"></drugfyi-drug>